ALBANY, New York, Feb. 12, 2015 /PRNewswire/ -- AMRI (NASDAQ:
AMRI) announced today its intention, subject to consultation with
its UK workforce, to close its UK facility in Holywell,
Wales, which provides chemical
development services and small- and large-scale manufacturing
services of active pharmaceutical ingredients (API).
"The original strategy for the Holywell site has been to act as
a conduit between Europe and
the United States. However, the
site has not been able to do this in a way that maximises value for
our customers and shareholders and is not aligned to the new
strategic direction of the company," said William S. Marth, president and chief executive
officer, AMRI. "We continue to move forward with our strategy to be
the preeminent supplier of custom and complex end-to-end services
to the pharmaceutical industry, which includes the development and
manufacture of high-value, niche active pharmaceutical ingredients
(APIs)."
The proposed closure of the U.K.-based operation may affect
approximately 64 positions. The company is commencing consultation
with employee representatives to consider ways of avoiding the
proposed redundancies, reducing the number of redundancies and
mitigating the impact of the redundancies. The company has no
further information to provide at this stage, pending the outcome
of consultation with its employees.
About AMRI
Albany Molecular Research Inc. (AMRI) is a
global contract research and manufacturing organization that has
been working with the Life Sciences industry to improve patient
outcomes and the quality of life for more than two decades. With
locations in North America,
Europe and Asia, our key business segments include
Discovery and Development Services (DDS), Active Pharmaceutical
Ingredients (API), and Drug Product Manufacturing. Our DDS segment
provides comprehensive services from hit identification to IND,
including expertise with diverse chemistry, library design and
synthesis, in vitro biology and pharmacology, drug
metabolism and pharmacokinetics, as well as natural products. API
Manufacturing supports the chemical development and cGMP
manufacture of complex API, including potent, controlled
substances, biologics, peptides, steroids, and cytotoxic compounds.
Drug Product Manufacturing supports pre-clinical through commercial
scale production of complex liquid-filled and lyophilized
parenteral formulations. For more information about AMRI, please
visit our website at www.amriglobal.com or follow us on Twitter
(@amriglobal).
About AMRI API Manufacturing
With demonstrated success
in large scale API Manufacturing, we offer the preeminence and
scale to support the chemical development and cGMP manufacture of
complex Active Pharmaceutical Ingredients (API). Our global
manufacturing footprint, which also includes manufacturing in
Europe and India, provides customers with access to
global markets and low-cost manufacturing of APIs or intermediates.
In addition, we have the skills and infrastructure to adequately
provide complex API research and development, analytical support
and support with global regulatory activities.